333 related articles for article (PubMed ID: 23155466)
1. Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice.
Unger WW; Pearson T; Abreu JR; Laban S; van der Slik AR; der Kracht SM; Kester MG; Serreze DV; Shultz LD; Griffioen M; Drijfhout JW; Greiner DL; Roep BO
PLoS One; 2012; 7(11):e49213. PubMed ID: 23155466
[TBL] [Abstract][Full Text] [Related]
2. Prevention of "Humanized" diabetogenic CD8 T-cell responses in HLA-transgenic NOD mice by a multipeptide coupled-cell approach.
Niens M; Grier AE; Marron M; Kay TW; Greiner DL; Serreze DV
Diabetes; 2011 Apr; 60(4):1229-36. PubMed ID: 21346176
[TBL] [Abstract][Full Text] [Related]
3. Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice.
Enée E; Martinuzzi E; Blancou P; Bach JM; Mallone R; van Endert P
J Immunol; 2008 Apr; 180(8):5430-8. PubMed ID: 18390725
[TBL] [Abstract][Full Text] [Related]
4. Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.
Babad J; Mukherjee G; Follenzi A; Ali R; Roep BO; Shultz LD; Santamaria P; Yang OO; Goldstein H; Greiner DL; DiLorenzo TP
Clin Exp Immunol; 2015 Mar; 179(3):398-413. PubMed ID: 25302633
[TBL] [Abstract][Full Text] [Related]
5. HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes.
Takaki T; Marron MP; Mathews CE; Guttmann ST; Bottino R; Trucco M; DiLorenzo TP; Serreze DV
J Immunol; 2006 Mar; 176(5):3257-65. PubMed ID: 16493087
[TBL] [Abstract][Full Text] [Related]
6. "Humanized" HLA transgenic NOD mice to identify pancreatic beta cell autoantigens of potential clinical relevance to type 1 diabetes.
Serreze DV; Marron MP; Dilorenzo TP
Ann N Y Acad Sci; 2007 Apr; 1103():103-11. PubMed ID: 17376821
[TBL] [Abstract][Full Text] [Related]
7. HLA-A2-matched peripheral blood mononuclear cells from type 1 diabetic patients, but not nondiabetic donors, transfer insulitis to NOD-scid/γc(null)/HLA-A2 transgenic mice concurrent with the expansion of islet-specific CD8+ T cells.
Whitfield-Larry F; Young EF; Talmage G; Fudge E; Azam A; Patel S; Largay J; Byrd W; Buse J; Calikoglu AS; Shultz LD; Frelinger JA
Diabetes; 2011 Jun; 60(6):1726-33. PubMed ID: 21521873
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel IGRP epitopes targeted in type 1 diabetes patients.
Jarchum I; Nichol L; Trucco M; Santamaria P; DiLorenzo TP
Clin Immunol; 2008 Jun; 127(3):359-65. PubMed ID: 18358785
[TBL] [Abstract][Full Text] [Related]
9. The frequency and immunodominance of islet-specific CD8+ T-cell responses change after type 1 diabetes diagnosis and treatment.
Martinuzzi E; Novelli G; Scotto M; Blancou P; Bach JM; Chaillous L; Bruno G; Chatenoud L; van Endert P; Mallone R
Diabetes; 2008 May; 57(5):1312-20. PubMed ID: 18305140
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers.
Velthuis JH; Unger WW; Abreu JR; Duinkerken G; Franken K; Peakman M; Bakker AH; Reker-Hadrup S; Keymeulen B; Drijfhout JW; Schumacher TN; Roep BO
Diabetes; 2010 Jul; 59(7):1721-30. PubMed ID: 20357361
[TBL] [Abstract][Full Text] [Related]
11. Beyond HLA-A*0201: new HLA-transgenic nonobese diabetic mouse models of type 1 diabetes identify the insulin C-peptide as a rich source of CD8+ T cell epitopes.
Antal Z; Baker JC; Smith C; Jarchum I; Babad J; Mukherjee G; Yang Y; Sidney J; Sette A; Santamaria P; DiLorenzo TP
J Immunol; 2012 Jun; 188(11):5766-75. PubMed ID: 22539795
[TBL] [Abstract][Full Text] [Related]
12. A Single L/D-Substitution at Q4 of the mInsA
Zhang M; Wang Y; Li X; Meng G; Chen X; Wang L; Lin Z; Wang L
Front Immunol; 2021; 12():713276. PubMed ID: 34526989
[TBL] [Abstract][Full Text] [Related]
13. Genetic and therapeutic control of diabetogenic CD8+ T cells.
Santamaria P
Novartis Found Symp; 2008; 292():130-6; discussion 136-45, 202-3. PubMed ID: 19209463
[TBL] [Abstract][Full Text] [Related]
14. Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice.
Marron MP; Graser RT; Chapman HD; Serreze DV
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13753-8. PubMed ID: 12361980
[TBL] [Abstract][Full Text] [Related]
15. CD8 and cytotoxic T cells in type 1 diabetes.
Peakman M
Novartis Found Symp; 2008; 292():113-9; discussion 119-29, 202-3. PubMed ID: 19203096
[TBL] [Abstract][Full Text] [Related]
16. HLA-B7-restricted islet epitopes are differentially recognized in type 1 diabetic children and adults and form weak peptide-HLA complexes.
Scotto M; Afonso G; Østerbye T; Larger E; Luce S; Raverdy C; Novelli G; Bruno G; Gonfroy-Leymarie C; Launay O; Lemonnier FA; Buus S; Carel JC; Boitard C; Mallone R
Diabetes; 2012 Oct; 61(10):2546-55. PubMed ID: 22997432
[TBL] [Abstract][Full Text] [Related]
17. Identification of autoreactive CD8+ T cell responses targeting chromogranin A in humanized NOD mice and type 1 diabetes patients.
Li Y; Zhou L; Li Y; Zhang J; Guo B; Meng G; Chen X; Zheng Q; Zhang L; Zhang M; Wang L
Clin Immunol; 2015 Jul; 159(1):63-71. PubMed ID: 25958206
[TBL] [Abstract][Full Text] [Related]
18. Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from prediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice.
Coppieters KT; Amirian N; von Herrath MG
Clin Exp Immunol; 2011 Aug; 165(2):155-62. PubMed ID: 21605113
[TBL] [Abstract][Full Text] [Related]
19. Characterization of immune response to novel HLA-A2-restricted epitopes from zinc transporter 8 in type 1 diabetes.
Xu X; Gu Y; Bian L; Shi Y; Cai Y; Chen Y; Chen H; Qian L; Wu X; Xu K; Mallone R; Davidson HW; Yu L; She J; Zhang M; Yang T
Vaccine; 2016 Feb; 34(6):854-62. PubMed ID: 26541133
[TBL] [Abstract][Full Text] [Related]
20. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
